Ogden Christopher 4
4 · CytomX Therapeutics, Inc. · Filed Jun 14, 2024
Insider Transaction Report
Form 4
Ogden Christopher
Chief Financial Officer
Transactions
- Award
Common Stock
2024-06-12+17,500→ 103,186 total - Award
Stock Option (Right to Buy)
2024-06-12+75,000→ 75,000 totalExercise: $1.49Exp: 2034-06-11→ Common Stock (75,000 underlying)
Footnotes (3)
- [F1]Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on June 12 of each year, with the first 1/3rd vesting on June 12, 2025, subject to the Reporting Person continuing as a service provider through each such date.
- [F2]Includes 77,810 RSUs.
- [F3]1/48th of the shares subject to the option vest on each monthly anniversary measured from June 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.